IPO WATCH- DBK Pharma’s drawn out relisting will take place in 4Q2017, the company’s chairman Hamdy El Debeky tells Al Borsa on Monday. The company’s relisting on the EGX had been marred by delays after it was initially expected to take place earlier this year. The Egyptian Financial Supervisory Authority had signed off on the company’s fair value assessment of EGP 3.1 per share back in July. We have yet to hear whether the company has settled on advisers for the listing.
More from Enterprise
The National Bank of Egypt and Banque Misr just hiked rates on CDs — moves that could see the EGP gain against the USD
NBE and BM both hiked rates on CDs by 125…
Miga guarantee unlocks USD 313 mn for National Bank of Egypt trade finance
Plus: Incolease taps securitization market with debut EGP 2 bn…
Swvl is not dropping off of Nasdaq just yet, as company turns to the black in 2025
The company turned a profit last year, allowing it to…
Kiwe gets Central Bank green light to launch nationwide
The startup is backed by our friends at EFG Hermes,…